v1.5 25 Mar 2021

ection 1: Project information													
Short project title*:	Biomarker-guided du	ration of antibiotic t	reatment for seps	is									
IRAS project ID* (or REC reference if no IRAS project ID is available):	209815												
Sponsor amendment reference number*:	NSA-14												
Sponsor amendment date* (enter as DD/MM/YY):	19 November 2021												
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	Changes 1) GP letter Nicola McGowan to U Change 2) Addition of Bwrdd lechyd Prifys University Hospitals	Jzma Manazar. If the following trial gol Betsi Cadwalad	sites (to enable st dr / Betsi Cadwala	udy recruitment ta	rgets):								
		•	Specific study	,									
Project type (select):		O Research tissue bank											
		O Research database											
Has the study been reviewed by a UKECA-recognised Res			1	O No									
Committee (REC) prior to this amendment?:		NHS/HSC RE											
What type of UKECA-recognised Research Ethics Commit is applicable? (select):	Ministry of Defence (MoDREC)												
) Ministry of De	Tence (MODREC)									
Is all or part of this amendment being resubmitted to the Ro Committee (REC) as a modified amendment (i.e. a subst amendment previously given an unfavourable opinion)?) Yes		No								
Where is the NHS/HSC Research Ethics Committee (REC	England	Wales	Scotland	Northern Ireland									
the study based?:		•	0	0	0								
Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?:	product (CTIMP)) Yes	•	No								
Was the study a clinical investigation or other study of a medoes the amendment make it one?:	edical device OR) Yes	+	No								
Did the study involve the administration of radioactive subsrequiring ARSAC review, OR does the amendment introdu		C) Yes	,	No								
Did the study involve the use of research exposures to ioni (not involving the administration of radioactive substances) amendment introduce this?:	•	C) Yes	,	No								
Did the study involve adults lacking capacity OR does the a introduce this?:	amendment	() Yes	1) No								
Did the study involve access to confidential patient informa direct care team without consent OR does the amendment) Yes		No								
Did the study involve prisoners OR does the amendment in	○ Yes ● No												
Did the study involve children OR does the amendment int	○ Yes ⑥ No												
Did the study involve NHS/HSC organisations prior to this a	amendment?:	Yes O No											
Did the study involve non-NHS/HSC organisations OR doe	es the amendment) Yes	No									
introduce them?:		England	Wales	Scotland	Northern Ireland								
•		Lingiana											
•		England	0	0	0								
introduce them?:			0	0	0								

Continu	٦.	Cummonia	٠.	ahanga(a)	
Section	2:	Summary of	ЭT	cnange(s)	

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the amendment tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, tick the "Add another change" box.

	Change 1
Area of change (select)*:	Study Documents

Specific change (select - only available when area of change is selected first)*:	Other minor change t questionnaires, letters participating organisa	s) that can be impl	emented within exi	isting resource in p	
Further information (free text - note that this field will adapt to the amount of text entered):	GP letter being edited to Uzma Manazar.	to reflect the char	nge of name for Tr	ial Manager, from	Nicola McGowan
Applicability:		England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations locate by this change?*:	d that will be affected	7	V	V	V
Will all participating NHS/HSC organisations be affected by some? (please note that this answer may affect the categoriange):			All	(O Some
				Add another cha	nge: 🗸
	Change 2				
Area of change (select)*:	Participating Organisa	ations			
Specific change (select - only available when area of change is selected first)*:	Addition of sites unde	ertaking the same a	activities as existin	g sites	
Further information (free text - note that this field will adapt to the amount of text entered):					
Applicability:		England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations locate by this change?*:	d that will be affected	7	V	4	V
Will all participating NHS/HSC organisations be affected by some? (please note that this answer may affect the categoriange):		(All	(O Some
				Add another cha	nge:

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]*: Mohammed Zubair

Email address*: Mohammed.Zubair@manchester.ac.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, proceed to submit the amendment online. The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for information only. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

							F	Review	bodie	s								
		UK	wide:			Eng	land a	ınd Wa	ales:		Scot	land:		N	orther	n Irelar	nd:	
	REC	Competent Authority MHRA - Medicines Competent Authority MHRA - Davices	4C	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	рврр	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons	National coordinating function	Category
Change 1:					(Y)				(Y)				(Y)				(Y)	С
Change 2:					(Y)				(Y)				(Y)				(Y)	New site
Overall reviews for the ame	endment:				•									•				

Full review:						Ν				Ν			Z		N
Notification only:						Υ				Υ			Υ		Υ
Overall amendment type:	No	Non-substantial, no study-wide review required													
Overall Category:	С														